Isolation and characterization of mutant CHO cell lines with compartment-specific resistance to brefeldin A.
22 CHOBFY (BFY) cell lines were isolated at a frequency 2-30 x 10(-7) from mutagenized populations on the basis of their ability to grow in the presence of 1 microgram/ml brefeldin A (BFA). Four of the five mutant lines tested are genetically stable and none of the mutant lines characterized degrade this drug. Immunofluorescence studies reveal that whereas early endosomes and the Golgi complex have nearly identical BFA sensitivities in the parent CHO line, the relative sensitivities of these two organelles were dramatically altered in all six mutant lines tested. Four cell lines maintain normal Golgi appearance at a BFA concentration as high as 10 micrograms/ml. Mutant lines show wide variation in the level of resistance to growth inhibition by BFA, but none of the mutant lines characterized grow above 2 micrograms/ml BFA. This specific growth inhibition is observed under conditions where Golgi morphology and function remain unaffected, suggesting that some factor(s) unrelated to Golgi function remains sensitive to BFA in BFY mutant lines. These observations provide strong evidence for the presence of multiple, organelle-specific targets for BFA. Cell-free measurements with membrane extracts establish that resistance to BFA in BFY-1 cells involves a membrane-associated factor distinct from ARFs and coatomers. This collection of mutant lines may prove valuable for the identification of intracellular target(s) for BFA and/or of effectors that interact upstream or downstream with these targets, thereby uncovering the cascade which regulates assembly of organelle-specific coats.
Department of Chemistry and Biochemistry, University of Colorado, Boulder 80309-0215.
J P
JP
Yan
M E
ME
Colon
L A
LA
Beebe
P
P
Melançon
D020727:ADP-Ribosylation Factors; D000818:Animals; D020126:Brefeldin A; D016466:CHO Cells / Q000502:physiology*; D002451:Cell Compartmentation; D002455:Cell Division / Q000187:drug effects; D020756:Coatomer Protein; D006224:Cricetinae; D003517:Cyclopentanes / Q000378:metabolism / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004351:Drug Resistance / Q000235:genetics; D019204:GTP-Binding Proteins / Q000032:analysis; D006056:Golgi Apparatus / Q000187:drug effects / Q000648:ultrastructure; D008562:Membrane Glycoproteins; D008565:Membrane Proteins / Q000378:metabolism; D008869:Microtubule-Associated Proteins / Q000032:analysis; D008954:Models, Biological; D009154:Mutation; D015388:Organelles / Q000187:drug effects* / Q000648:ultrastructure; D010641:Phenotype; D012641:Selection, Genetic; D014759:Viral Envelope Proteins / Q000378:metabolism
D020756:Coatomer Protein; D003517:Cyclopentanes; C028391:G protein, vesicular stomatitis virus; D008562:Membrane Glycoproteins; D008565:Membrane Proteins; D008869:Microtubule-Associated Proteins; D014759:Viral Envelope Proteins; D020126:Brefeldin A; D019204:GTP-Binding Proteins; D020727:ADP-Ribosylation Factors